# Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis

> **NCT00037102** · PHASE4 · COMPLETED · sponsor: **MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute** · enrollment: 16 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** interferon beta 1a
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00037102
- **Lead sponsor:** MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00037102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00037102, "Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00037102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*